VDD has been implicated as a risk in the development of MASLD; however, animal and human models have suggested variable upregulation and downregulation of VDR activity, rather than VD concentration, are responsible for the hepatocyte degradation and immune dysfunction observed as MASLD progresses [110]. Here, VDR is linked to metabolic dysfunction-associated steatotic liver disease.